Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HA-1 TCR T cells for Recurrent Acute Leukemia After Allogeneic HCT
NCT03326921Phase 1Recruiting
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Feb 2018
- Primary completion
- Oct 2027
- Modality
- Gene Editing, Gene Silencing, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR in leukemia and myelodysplastic syndrome (MDS), sponsored by Fred Hutchinson Cancer Center. Primary endpoints: Feasibility of manufacturing minor H antigen (HA-1) T cell receptor (TCR) CD8+ and CD4+ T cells at Day 0, Feasibility of administering minor H antigen (HA-1) T cell receptor (TCR) CD8+ and CD4+ T cells at Day 0 and 1 more. Started Feb 2018; status: recruiting.
02
Drugs
CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR
03
Conditions
leukemiamyelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT03326921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03326921.